About Cabaletta Bio, Inc.
https://www.cabalettabio.comCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
CEO
Steven A. Nichtberger
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 27
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
Guggenheim
Buy
UBS
Buy
Cantor Fitzgerald
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:9.68M
Value:$20.81M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:8.83M
Value:$18.98M
JENNISON ASSOCIATES LLC
Shares:8.5M
Value:$18.27M
Summary
Showing Top 3 of 85
About Cabaletta Bio, Inc.
https://www.cabalettabio.comCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $46.24M ▲ | $-44.87M ▲ | 0% | $-0.44 ▲ | $-43.94M ▲ |
| Q2-2025 | $0 | $45.44M ▲ | $-45.13M ▼ | 0% | $-0.73 | $-44.09M ▼ |
| Q1-2025 | $0 | $36.65M ▲ | $-35.94M ▼ | 0% | $-0.73 ▼ | $-35.16M ▼ |
| Q4-2024 | $0 | $33.32M ▲ | $-32.59M ▼ | 0% | $-0.65 ▼ | $-31.37M ▼ |
| Q3-2024 | $0 | $32.62M | $-30.63M | 0% | $-0.63 | $-30.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $159.93M ▼ | $189.76M ▼ | $50.29M ▲ | $139.47M ▼ |
| Q2-2025 | $194.68M ▲ | $224.5M ▲ | $46.02M ▲ | $178.48M ▲ |
| Q1-2025 | $131.83M ▼ | $165.14M ▼ | $43.59M ▲ | $121.55M ▼ |
| Q4-2024 | $163.96M ▼ | $185.05M ▼ | $32.71M ▲ | $152.34M ▼ |
| Q3-2024 | $183.01M | $204.41M | $30.17M | $174.24M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-44.87M ▲ | $-34.51M ▼ | $-50.08M ▼ | $-806K ▼ | $-85.41M ▼ | $-34.59M ▼ |
| Q2-2025 | $-45.13M ▼ | $-30.43M ▲ | $-49.2M ▼ | $93.37M ▲ | $13.78M ▲ | $-30.59M ▲ |
| Q1-2025 | $-35.94M ▼ | $-30.8M ▼ | $-785K ▼ | $-552K ▼ | $-32.13M ▼ | $-31.59M ▼ |
| Q4-2024 | $-32.59M ▼ | $-23.12M ▼ | $12.12M ▼ | $4.37M ▲ | $-6.65M ▲ | $-23.5M ▼ |
| Q3-2024 | $-30.63M | $-20.32M | $12.25M | $71K | $-8.01M | $-20.58M |
CEO
Steven A. Nichtberger
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 27
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
Guggenheim
Buy
UBS
Buy
Cantor Fitzgerald
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:9.68M
Value:$20.81M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:8.83M
Value:$18.98M
JENNISON ASSOCIATES LLC
Shares:8.5M
Value:$18.27M
Summary
Showing Top 3 of 85